Cargando…
Antibacterial and anti-biofilm activity of radezolid against Staphylococcus aureus clinical isolates from China
Although the potent antibacterial ability of radezolid against Staphylococcus aureus has been widely reported worldwide, its antibacterial and anti-biofilm activity against the S. aureus clinical isolates from China remains elusive. In this study, the minimum inhibitory concentration (MIC) of radezo...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169660/ https://www.ncbi.nlm.nih.gov/pubmed/37180277 http://dx.doi.org/10.3389/fmicb.2023.1131178 |
_version_ | 1785039087616393216 |
---|---|
author | Wang, Cong Xiong, Yanpeng Bao, Chai Wei, Ying Wen, Zewen Cao, Xinyi Yu, Zhijian Deng, Xiangbing Li, Guiqiu Deng, Qiwen |
author_facet | Wang, Cong Xiong, Yanpeng Bao, Chai Wei, Ying Wen, Zewen Cao, Xinyi Yu, Zhijian Deng, Xiangbing Li, Guiqiu Deng, Qiwen |
author_sort | Wang, Cong |
collection | PubMed |
description | Although the potent antibacterial ability of radezolid against Staphylococcus aureus has been widely reported worldwide, its antibacterial and anti-biofilm activity against the S. aureus clinical isolates from China remains elusive. In this study, the minimum inhibitory concentration (MIC) of radezolid was determined in S. aureus clinical isolates from China using the agar dilution method, and the relationship between radezolid susceptibility and ST distribution was also investigated. The anti-biofilm activity of radezolid against S. aureus was determined by a crystal violet assay and compared with that of linezolid and contezolid. The quantitative proteomics of S. aureus treated with radezolid was analyzed, and the genetic mutations in radezolid-induced resistant S. aureus were determined by whole-genome sequencing. The dynamic changes in transcriptional expression levels of several biofilm-related genes were analyzed by quantitative RT-PCR. Our data showed that radezolid MIC ranged from ≤0.125 to 0.5 mg/L, which was almost 1/4 × MIC of linezolid against S. aureus, indicating the greater antibacterial activity of radezolid than linezolid. The S. aureus clinical isolates with radezolid MICs of 0.5 mg/L were most widely distributed in ST239 of MRSA and ST7 of MSSA. Moreover, the more robust anti-biofilm activity of radezolid with subinhibitory concentrations (1/8 × MIC and 1/16 × MIC) was demonstrated against S. aureus when compared with that of contezolid and linezolid. Genetic mutations were found in glmS, 23S rRNA, and DUF1542 domain-containing protein in radezolid-induced resistant S. aureus selected by in vitro induction of drug exposure. Quantitative proteomic analysis of S. aureus indicated that the global expression of some biofilm-related and virulence-related proteins was downregulated. Quantitative RT-PCR further confirmed that the expressions of some downregulated biofilm-related proteins, including sdrD, carA, sraP, hlgC, sasG, spa, sspP, fnbA, and oatA, were decreased after 12 h and 24 h of exposure to radezolid. Conclusively, radezolid shows robust antibacterial and anti-biofilm activity against S. aureus clinical isolates from China when compared with contezolid and linezolid. |
format | Online Article Text |
id | pubmed-10169660 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101696602023-05-11 Antibacterial and anti-biofilm activity of radezolid against Staphylococcus aureus clinical isolates from China Wang, Cong Xiong, Yanpeng Bao, Chai Wei, Ying Wen, Zewen Cao, Xinyi Yu, Zhijian Deng, Xiangbing Li, Guiqiu Deng, Qiwen Front Microbiol Microbiology Although the potent antibacterial ability of radezolid against Staphylococcus aureus has been widely reported worldwide, its antibacterial and anti-biofilm activity against the S. aureus clinical isolates from China remains elusive. In this study, the minimum inhibitory concentration (MIC) of radezolid was determined in S. aureus clinical isolates from China using the agar dilution method, and the relationship between radezolid susceptibility and ST distribution was also investigated. The anti-biofilm activity of radezolid against S. aureus was determined by a crystal violet assay and compared with that of linezolid and contezolid. The quantitative proteomics of S. aureus treated with radezolid was analyzed, and the genetic mutations in radezolid-induced resistant S. aureus were determined by whole-genome sequencing. The dynamic changes in transcriptional expression levels of several biofilm-related genes were analyzed by quantitative RT-PCR. Our data showed that radezolid MIC ranged from ≤0.125 to 0.5 mg/L, which was almost 1/4 × MIC of linezolid against S. aureus, indicating the greater antibacterial activity of radezolid than linezolid. The S. aureus clinical isolates with radezolid MICs of 0.5 mg/L were most widely distributed in ST239 of MRSA and ST7 of MSSA. Moreover, the more robust anti-biofilm activity of radezolid with subinhibitory concentrations (1/8 × MIC and 1/16 × MIC) was demonstrated against S. aureus when compared with that of contezolid and linezolid. Genetic mutations were found in glmS, 23S rRNA, and DUF1542 domain-containing protein in radezolid-induced resistant S. aureus selected by in vitro induction of drug exposure. Quantitative proteomic analysis of S. aureus indicated that the global expression of some biofilm-related and virulence-related proteins was downregulated. Quantitative RT-PCR further confirmed that the expressions of some downregulated biofilm-related proteins, including sdrD, carA, sraP, hlgC, sasG, spa, sspP, fnbA, and oatA, were decreased after 12 h and 24 h of exposure to radezolid. Conclusively, radezolid shows robust antibacterial and anti-biofilm activity against S. aureus clinical isolates from China when compared with contezolid and linezolid. Frontiers Media S.A. 2023-04-26 /pmc/articles/PMC10169660/ /pubmed/37180277 http://dx.doi.org/10.3389/fmicb.2023.1131178 Text en Copyright © 2023 Wang, Xiong, Bao, Wei, Wen, Cao, Yu, Deng, Li and Deng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Microbiology Wang, Cong Xiong, Yanpeng Bao, Chai Wei, Ying Wen, Zewen Cao, Xinyi Yu, Zhijian Deng, Xiangbing Li, Guiqiu Deng, Qiwen Antibacterial and anti-biofilm activity of radezolid against Staphylococcus aureus clinical isolates from China |
title | Antibacterial and anti-biofilm activity of radezolid against Staphylococcus aureus clinical isolates from China |
title_full | Antibacterial and anti-biofilm activity of radezolid against Staphylococcus aureus clinical isolates from China |
title_fullStr | Antibacterial and anti-biofilm activity of radezolid against Staphylococcus aureus clinical isolates from China |
title_full_unstemmed | Antibacterial and anti-biofilm activity of radezolid against Staphylococcus aureus clinical isolates from China |
title_short | Antibacterial and anti-biofilm activity of radezolid against Staphylococcus aureus clinical isolates from China |
title_sort | antibacterial and anti-biofilm activity of radezolid against staphylococcus aureus clinical isolates from china |
topic | Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169660/ https://www.ncbi.nlm.nih.gov/pubmed/37180277 http://dx.doi.org/10.3389/fmicb.2023.1131178 |
work_keys_str_mv | AT wangcong antibacterialandantibiofilmactivityofradezolidagainststaphylococcusaureusclinicalisolatesfromchina AT xiongyanpeng antibacterialandantibiofilmactivityofradezolidagainststaphylococcusaureusclinicalisolatesfromchina AT baochai antibacterialandantibiofilmactivityofradezolidagainststaphylococcusaureusclinicalisolatesfromchina AT weiying antibacterialandantibiofilmactivityofradezolidagainststaphylococcusaureusclinicalisolatesfromchina AT wenzewen antibacterialandantibiofilmactivityofradezolidagainststaphylococcusaureusclinicalisolatesfromchina AT caoxinyi antibacterialandantibiofilmactivityofradezolidagainststaphylococcusaureusclinicalisolatesfromchina AT yuzhijian antibacterialandantibiofilmactivityofradezolidagainststaphylococcusaureusclinicalisolatesfromchina AT dengxiangbing antibacterialandantibiofilmactivityofradezolidagainststaphylococcusaureusclinicalisolatesfromchina AT liguiqiu antibacterialandantibiofilmactivityofradezolidagainststaphylococcusaureusclinicalisolatesfromchina AT dengqiwen antibacterialandantibiofilmactivityofradezolidagainststaphylococcusaureusclinicalisolatesfromchina |